Country: European Union
Language: English
Source: EMA (European Medicines Agency)
Evolocumab
Amgen Europe B.V.
C10AX13
evolocumab
Lipid modifying agents
Dyslipidemias; Hypercholesterolemia
Hypercholesterolaemia and mixed dyslipidaemiaRepatha is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:in combination with a statin or statin with other lipid lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin or,alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.Homozygous familial hypercholesterolaemiaRepatha is indicated in adults and adolescents aged 12 years and over with homozygous familial hypercholesterolaemia in combination with other lipid-lowering therapies.Established atherosclerotic cardiovascular diseaseRepatha is indicated in adults with established atherosclerotic cardiovascular disease (myocardial infarction, stroke or peripheral arterial disease) to reduce cardiovascular risk by lowering LDL-C levels, as an adjunct to correction of other risk factors:in combination with the maximum tolerated dose of a statin with or without other lipid-lowering therapies or,alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.For study results with respect to effects on LDL-C, cardiovascular events and populations studied see section 5.1.
Revision: 24
Authorised
2015-07-17
45 B. PACKAGE LEAFLET 46 PACKAGE LEAFLET: INFORMATION FOR THE USER REPATHA 140 MG SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE evolocumab READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor, pharmacist or nurse. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. - The warnings and instructions in this document are intended for the person taking the medicine. If you are a parent or carer responsible for giving the medicine to someone else, such as a child, you will need to apply the information accordingly WHAT IS IN THIS LEAFLET 1. What Repatha is and what it is used for 2. What you need to know before you use Repatha 3. How to use Repatha 4. Possible side effects 5. How to store Repatha 6. Contents of the pack and other information 1. WHAT REPATHA IS AND WHAT IT IS USED FOR WHAT REPATHA IS AND HOW IT WORKS Repatha is a medicine that lowers levels of ‘bad’ cholesterol, a type of fat, in the blood. Repatha contains the active substance evolocumab, a monoclonal antibody (a type of specialised protein designed to attach to a target substance in the body). Evolocumab is designed to attach to a substance called PCSK9 that affects the liver’s ability to take in cholesterol. By attaching to, and mopping up PCSK9, the medicine increases the amount of cholesterol entering the liver and so lowers the level of cholesterol in the blood. WHAT REPATHA IS USED FOR _ _ Repatha is used in addition to your cholesterol lowering diet if you are: • an adult with a high cholesterol level in your blood (primary hypercholesterolaemia [heterozygous familial and non-familial] or mixed dyslipidaemia). It is Read the complete document
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE MEDICINAL PRODUCT Repatha 140 mg solution for injection in pre-filled syringe Repatha 140 mg solution for injection in pre-filled pen Repatha 420 mg solution for injection in cartridge 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Repatha 140 mg solution for injection in pre-filled syringe Each pre-filled syringe contains 140 mg of evolocumab in 1 mL of solution. Repatha 140 mg solution for injection in pre-filled pen Each pre-filled pen contains 140 mg of evolocumab in 1 mL of solution. Repatha 420 mg solution for injection in cartridge Each cartridge contains 420 mg of evolocumab in 3.5 mL of solution (120 mg/mL). Repatha is a human IgG2 monoclonal antibody produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection (injection). Solution for injection (injection) in pre-filled pen (SureClick). Solution for injection (injection) (automated mini-doser). The solution is clear to opalescent, colourless to yellowish, and practically free from particles. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Hypercholesterolaemia and mixed dyslipidaemia Repatha is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, and in paediatric patients aged 10 years and over with heterozygous familial hypercholesterolaemia, as an adjunct to diet: • in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin or, • alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated. Homozygous familial hypercholesterolaemia Repatha is indicated in adults and paediatric patients aged 10 years and over with homozygous familial hypercholesterolaemia in combination with other lipid-lowering therapies. 3 Established atheroscleroti Read the complete document